MACLEODS PHARMS
GenericsMACLEODS PHARMS is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Neurology. Key products include LAMIVUDINE AND ZIDOVUDINE.
MACLEODS PHARMS's Key Drugs
MACLEODS PHARMS's core commercial portfolio centers on CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE AND VALSARTAN, spanning Cardiovascular and Infectious Disease — its most strategically important drugs approved in the last 15 years.
Gastrointestinal Disorder
Hypertension
Hypertension
Overactive Bladder
Heart Failure
MACLEODS PHARMS's Recent FDA Approvals
MACLEODS PHARMS secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
MACLEODS PHARMS's Therapeutic Areas
MACLEODS PHARMS's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MACLEODS PHARMS's Top Competitors
MACLEODS PHARMS's closest competitors by therapeutic-area and drug-target overlap include Merck, Novo Nordisk, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MACLEODS PHARMS Pipeline Snapshot
Active clinical trials for MACLEODS PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (14)
Discontinued (9)
Company Info
- First Approval
- 1998-10-28
- Latest
- 2026-11-04
- Applications
- 192